Predicting Response to Atomoxetine and Methylphenidate
ID Number 03-0612Principal Investigator(s)
Department(s) or Division(s)
Center of Excellence in ADHD and Related Disorders
The purpose of this study is three-fold. First, to compare the efficacy of four to five weeks of treatment with methylphenidate (Concerta™) and atomoxetine (Strattera™) on ADHD symptoms and associated functional impairment. Second, to evaluate differences in adverse effects and palatability between the two treatments. Third, to evaluate clinical and pharmacogenetic moderators of response to the two treatments.
Beth K. Krone, CRC
Recruiting Patients: No